Conference Reports for NATAP

65th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 7-11 2014 Back

Simeprevir+Sofosbuvir at AASLD       AASLD: Performance and Cost -Effectiveness of Simeprevir and Sofosbuvir Based HCV treatment in Real World Clinical Practice - 2014 at Mt Sinai Hospital NY - (12/11/14)   AASLD: Efficacy and Safety of Sofosbuvir and Simeprevir in Patients with Advanced HCV Cirrhosis - (12/11/14)   AASLD: Interferon Ineligible subjects treated with Simeprevir in special population (Schizophrenic, severe major depression, severe bipolar and schizoaffective disorder) in genotype 1 subjects with Ribavirin Effecr; in naive chronic hepatitis C (CHC) genotype 1 subjects. An open label prospective clinical pilot study; INSPIRE C study - (12/11/14)   AASLD: Single Center Experience with Simeprevir / Sofosbuvir Combination Therapy for Recurrent Hepatitis C Virus Infection in Liver Transplant Recipients - (12/11/14)   AASLD: Successful treatment of post liver transplant patients with genotype 1 hepatitis C virus with sofosbuvir and simeprevir - (12/11/14)   AASLD: Post-Liver Transplant Treatment of Hepatitis C with a Combination of Sofosbuvir, Simeprevir +/- Ribavirin at a High Volume Academic Transplant Center - (12/11/14)   AASLD: Evaluation of efficacy of sofosbuvirand simeprevir-based regimens in a real-life population of HCV patients with cirrhosis; data from the TRIO network - (12/09/14)   AASLD: Efficacy of sofosbuvir and simeprevir-based regimens for HCV treatment-experienced GT1 patients in a real-life setting; data from the TRIO network - (12/09/14)   AASLD: Safety and Efficacy of New DAA---based Therapy for Hepatitis C Post---Transplant: Interval Results from the HCV---TARGET Longitudinal, Observational Study - (11/11/14)   AASLD: Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort HCV-TARGET - (11/10/14)   AASLD: Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network - Academic and community treatment of a real-world, heterogeneous population - (11/10/14)   AASLD: Multicenter Experience using Sofosbuvir and Simeprevir with/without Ribavirin to Treat HCV Genotype 1 after Liver Transplantation - (11/10/14)   OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic Hepatitis C Infection - (11/06/14)   65th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 7-11 2014